Supernus Pharmaceuticals, Inc. (SUPN)
$42.67+1.26%Close
BUYRECOVERY · day 47
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.5B
- Beta
- 0.56
- P/E (TTM)
- -22.29
- Short % float
- 9.16%
- Days to cover
- 7.4
- SI change
- -0.1%
- 1W
- +0.68%
- 1M
- +2.35%
- vs SPY 1W
- -0.48%
- vs SPY 1M
- -0.64%
Industry peers
FMP comparable companies · ranked by market cap
- GRALBUYGRAIL Inc.$6.6BRECOVERYQ 68$154.08+6.01%
- LNTHSELLLantheus Holdings, Inc.$6.5BBEARQ 31$100.19+0.03%
- AMRXBUYAmneal Pharmaceuticals, Inc.$6.5BBULLQ 15$20.35+1.32%
- CNTACentessa Pharmaceuticals plc$6.3B$40.50
- CGONSELLCG Oncology Inc.$6.1BCRISISQ 25$68.71+0.89%
- INDVBUYIndivior Pharmaceuticals Inc$4.5BRECOVERYQ 20$35.99+1.07%
- XENESELLXenon Pharmaceuticals Inc.$3.6BCRISISQ 22$37.57+0.77%
- HCMBUYHUTCHMED (China) Limited$2.5BRECOVERYQ 5$14.31+3.15%
- BHCSELLBausch Health Companies Inc.$2.2BRECOVERYQ 2$5.89+0.00%
- PRGOBUYPerrigo Company plc$2.0BRECOVERYQ 4$14.44+3.86%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on SUPN?
- LOPJLB’s latest quantitative signal on Supernus Pharmaceuticals, Inc. (SUPN) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is SUPN in?
- Supernus Pharmaceuticals, Inc. (SUPN) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Supernus Pharmaceuticals, Inc. (SUPN) do?
- Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release …